Therapeutic Supplemental Oxygen Delivery in COVID-19
Respirogen, Inc., BOULDER, Colorado, United States
Technologies for improved delivery of supplemental oxygen
Tech Brief: COVID-19 patients suffer insufficient transfer of oxygen via the lungs (hypoxia) leading to organ failure/death. Respirogen Micro-Oxygen provides oxygen in a stable phospholipid shell, with oxygen absorption from the colon to address systemic hypoxia independent of the lungs. The procedure augments high flow nasal cannula and ventilator protocols.
Early-stage Startup (Seed)
FIGURES OF MERIT Value Proposition: Respirogen technology is targeted to hypoxia treatment in ARDS (40% mortality), COVID, and lung compromised patients where oxygen delivered to the body without reliance on the lungs will reduce ventilator associated complications, improve outcomes, and decrease cost of care for patients in the ICU. RMO therapy opens commercial markets for hypoxia therapy outside of critical care settings, and in a novel delivery independent of, or in addition to, ventilators. Commercialization of RMO allows the partner to redefine oxygen delivery modalities and point of care, with potential to reduce system reliance on ventilators, reducing system expense for critical care in lung compromise. The therapy may be delivered as a single use delivery system with a single patient therapeutic, shifting oxygen delivery from capital equipment to disposable sales, allowing onset to resolution procedure coverage in hypoxia. The therapy allows COVID-19 hypoxia treatment in non-intensive care environments, and in critical care will supplement ventilator protocols, reducing patient days on ventilation and potentially reducing need for ECMO therapy.